Astellas Pharma Inc. news covers developments from a Japanese pharmaceutical company and its unsponsored ADR, including oncology data, licensing activity, research collaborations and patient-focused programs. Recurring updates include clinical presentations for approved cancer therapies such as XTANDI with Pfizer, oncology pipeline additions such as the clinical-stage antibody-drug conjugate XNW27011, and collaborations that support drug-discovery startups in Japan, Korea and U.S. life-science incubators.
Company announcements also address patient advocacy initiatives, research-center and incubator access through programs such as SakuLab™-Tsukuba, and business-development agreements that expand Astellas' therapeutic and technology capabilities.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.